{"id":12827,"date":"2026-04-27T17:44:10","date_gmt":"2026-04-27T17:44:10","guid":{"rendered":"https:\/\/www.europesays.com\/japan\/12827\/"},"modified":"2026-04-27T17:44:10","modified_gmt":"2026-04-27T17:44:10","slug":"img-pharma-enters-into-definitive-agreement-to-acquire-matsumoto-pharmaceutical-in-japan","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/japan\/12827\/","title":{"rendered":"IMG Pharma enters into definitive agreement to acquire Matsumoto Pharmaceutical in Japan"},"content":{"rendered":"<p>\t\t\t\t\t\tIMG Pharma enters into definitive agreement to acquire Matsumoto Pharmaceutical in Japan<\/p>\n<p class=\"float-left\">April 27, 2026 | Monday | News<\/p>\n<p>\t\t\t\t\t\t\tTo support the development of a scalable pharmaceutical and health product platform<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/japan\/wp-content\/uploads\/2026\/04\/22-27556.jpg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"image credit- shutterstock\"\/><\/p>\n<p class=\"mt-3 text-center\">image credit- shutterstock<\/p>\n<p style=\"text-align: justify;\">IMG Pharmaceutical Co, a majority-owned subsidiary of IMG Japan, the Group&#8217;s holding company, has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co, a Japanese pharmaceutical manufacturer.<\/p>\n<p style=\"text-align: justify;\">IMG Medical Group operates an integrated healthcare platform across Asia, providing structured clinical services and long-term health management across the full lifecycle of care\u2014from life creation and optimisation to preservation. Within this framework, IMG Pharma serves as the Group&#8217;s pharmaceutical and product platform, translating clinical needs and medical pathways into standardized, scalable pharmaceutical and health products.<\/p>\n<p style=\"text-align: justify;\">Founded in 1948, Matsumoto Pharmaceutical has established a mature OTC product system, with more than 50 registered drug approvals across Class 1, 2, and 3 categories and over 30 trademarks. Its product portfolio spans digestive, respiratory, and dermatological areas, as well as metabolic and physiological function-related segments.<\/p>\n<p style=\"text-align: justify;\">Matsumoto Pharmaceutical currently operates two pharmaceutical manufacturing facilities in the Kansai region, with a combined site area exceeding 10,000 square meters, supporting its established production and OTC manufacturing capabilities.<\/p>\n<p style=\"text-align: justify;\">IMG Pharma operates with Kobe as its core R&amp;D and industrialization hub, leveraging the Kobe Biomedical Innovation Cluster (KBIC), one of Japan&#8217;s leading life science ecosystems. The Company is advancing research and product development across regenerative and bioactive domains, including DPSC (dental pulp stem cell-related pathways), iPS cell-related technologies, placenta-derived bioactive components, and NAD-related compounds, with a focus on translational development and productisation.<\/p>\n<p style=\"text-align: justify;\">This integration combines IMG Pharma&#8217;s biopharmaceutical and translational capabilities with Matsumoto Pharmaceutical&#8217;s manufacturing foundation and OTC product system, forming a multi-layered product capability structure. It is expected to support the development of a scalable pharmaceutical and health product platform addressing long-term health management needs.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"IMG Pharma enters into definitive agreement to acquire Matsumoto Pharmaceutical in Japan April 27, 2026 | Monday |&hellip;\n","protected":false},"author":2,"featured_media":12828,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[10662,8232,8,10661],"class_list":["post-12827","post","type-post","status-publish","format-standard","has-post-thumbnail","category-japan","tag-acquire","tag-agreement","tag-japan","tag-pharma"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/12827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/comments?post=12827"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/12827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media\/12828"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media?parent=12827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/categories?post=12827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/tags?post=12827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}